Chester County News and Community Website
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory …
Read More
WASHINGTON. D.C. — U.S. Department of Veterans Affairs (VA) researchers and Veteran volunteers from the Atlanta and San Antonio VA medical centers were part of a recently published study that yielded crucial …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) reported its financial and operational results for the second quarter ended June 30, 2020.
Read MoreWASHINGTON, D.C. — The U.S. Food and Drug Administration this week approved Keytruda (pembrolizumab) for intravenous injection for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced preliminary data from the first 10 patients in the safety cohort of ILLUMINATE-206, a Phase 2, open-label, multi-center study to evaluate …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist, will be presented …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced final topline data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist.
Read More